SEC Filing Summary: ReShape Lifesciences Inc. (RSLS)
Business Context and Reporting Period
This Form 8-K was filed by ReShape Lifesciences Inc. on May 28, 2025. The registrant is a Delaware corporation with principal executive offices in Irvine, CA, and its common stock trades on The Nasdaq Capital Market under the symbol RSLS. The filing addresses a critical corporate governance and listing status event.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the failure to meet the Nasdaq minimum stockholders' equity requirement of $2,500,000 as of the November 25, 2024 notification date. No debt or liquidity figures are explicitly stated in this document.
Material Changes
The material change reported is the determination by Nasdaq to delist the Company's securities. On November 25, 2024, the Company was notified of non-compliance with the minimum stockholders' equity rule (Listing Rule 5550(b)). Although granted an extension until May 27, 2025, Nasdaq determined the Company failed to meet the terms of this extension by the deadline.
Outlook, Risks, and Management Commentary
Management intends to appeal Nasdaq's delisting decision to a hearings panel. This appeal is expected to stay the suspension of trading pending the panel's decision. The filing explicitly states there is no assurance that the hearings panel will grant continued listing or that the Company can maintain compliance with other Nasdaq rules. If no appeal is filed by June 4, 2025, trading will be suspended on June 6, 2025, and a Form 25-NSE will be filed to remove the securities from Nasdaq.
Investor Verification Checklist
- Verify the status of the appeal to the Nasdaq hearings panel and the expected timeline for a decision.
- Confirm the current stockholders' equity balance to understand the gap relative to the $2,500,000 requirement.
- Monitor for the filing of Form 25-NSE if the appeal is unsuccessful or not filed by June 4, 2025.
- Check for any subsequent filings regarding alternative listing venues or capital raising efforts to restore compliance.